Sutro Biopharma

Yahoo Finance • 26 days ago

Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Summit Insights upgraded Qualcomm (QCO... Full story

Yahoo Finance • 26 days ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Quick Read As expected, the Federal Reserve did not lower rates at its meeting, which is likely the last time we will see Jay Powell as Chairman. The Chairman said he expects the first-quarter gross domestic product to take a hit from the... Full story

Yahoo Finance • 27 days ago

Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now

Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milesto... Full story

Yahoo Finance • last month

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity acr... Full story

Yahoo Finance • 3 months ago

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), toda... Full story

Yahoo Finance • 5 months ago

Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sutro Biopharma, Inc. SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug co... Full story

Yahoo Finance • 6 months ago

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel... Full story

Yahoo Finance • 6 months ago

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor webcast today at 7:00AM PT / 10:00... Full story

Yahoo Finance • 7 months ago

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at... Full story

Yahoo Finance • 7 months ago

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced th... Full story

Yahoo Finance • 7 months ago

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it... Full story

Yahoo Finance • 8 months ago

Sutro Biopharma announces restructuring to extend cash runway

* Sutro Biopharma (NASDAQ:STRO [https://seekingalpha.com/symbol/STRO]) announced [https://seekingalpha.com/pr/20248029-sutro-biopharma-announces-operational-restructuring-intended-to-extend-cash-runway-through] on Monday an organizationa... Full story

Yahoo Finance • 8 months ago

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format an... Full story

Yahoo Finance • 8 months ago

WES Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Western Midstream Partners LP (Symbol: WES) crossed below their 200 day moving average of $26.72, changing hands as low as $26.51 per share. Western Midstream Partners LP shares are currently trading off a... Full story

Yahoo Finance • 10 months ago

Sutro Biopharma GAAP EPS of -$0.14, revenue of $63.7M

* Sutro Biopharma press release [https://seekingalpha.com/pr/20194321-sutro-biopharma-reports-second-quarter-2025-financial-results-and-business-highlights] (NASDAQ:STRO [https://seekingalpha.com/symbol/STRO]): Q2 GAAP EPS of -$0.14. *... Full story

Yahoo Finance • 10 months ago

Sutro Biopharma Inc (NASDAQ:STRO) Reports Q2 2025 Revenue Beat and Narrower Losses, Shares Rise in After-Hours Trading

SUTRO BIOPHARMA INC (NASDAQ:STRO [https://www.chartmill.com/stock/quote/STRO]) reported its second-quarter 2025 financial results, delivering a significant revenue beat while narrowing its losses compared to analyst expectations. The compa... Full story

Yahoo Finance • 10 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research... Full story

Yahoo Finance • 10 months ago

Earnings call transcript: Strongpoint Q2 2025 sees positive EBITDA, 18% revenue growth

Strongpoint ASA reported strong financial results for the second quarter of 2025, showcasing significant improvements in revenue and profitability. The company achieved an 18% year-over-year revenue increase, reaching NOK 350 million. EBIT... Full story

Yahoo Finance • 10 months ago

StrongPoint Q2 2025 slides: Revenue up 18%, EBITDA improves amid retail tech expansion

Introduction & Market Context StrongPoint ASA (OB:STRO) presented its second quarter 2025 results on July 11, showing continued revenue growth and improved profitability as the retail technology provider expands its footprint across Europ... Full story

Yahoo Finance • 11 months ago

Piper Sandler upgrades Sutro Biopharma stock rating on pipeline progress

Piper Sandler upgraded Sutro Biopharma (NASDAQ:STRO) from Neutral to Overweight on Monday, setting a price target of $2.00 for the biopharmaceutical company focused on antibody-drug conjugates (ADCs). According to InvestingPro data, the... Full story